SCHEMBL16636350

SCHEMBL16636350

COC(=O)[C@@H]1CCCC[C@H]1c1nc(-c2ccc(F)cc2)oc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.38
HTR3A P46098 2/20 0.37
TP53 P04637 1/20 0.37
CTSK P43235 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
ACKR3 P25106 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HDAC6 Q9UBN7 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SLC6A3 Q01959 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636352 1.00 SLC6A2 (0.45) SLC6A2SLC6A4ALDH1A1KDM4EHPGD
SCHEMBL16635861 0.86 SMN1; SMN2 (0.38) ALDH1A1KDM4EHPGDHTR3ATP53
SCHEMBL16638066 0.81 CTSK (0.48) SLC6A2SLC6A4ALDH1A1KDM4EHPGD
SCHEMBL16617294 0.81 CTSK (0.48) SLC6A2SLC6A4ALDH1A1KDM4EHPGD
SCHEMBL16617295 0.81 CTSK (0.48) SLC6A2SLC6A4ALDH1A1KDM4EHPGD
SCHEMBL16636407 0.78 SLC6A2 (0.45) SLC6A2SLC6A4ALDH1A1KDM4ECTSK
SCHEMBL16636408 0.78 SLC6A2 (0.45) SLC6A2SLC6A4ALDH1A1KDM4ECTSK
SCHEMBL16636338 0.78 HPGD (0.48) SLC6A2SLC6A4HPGDGAAHDAC6
SCHEMBL16636340 0.78 HPGD (0.48) SLC6A2SLC6A4HPGDGAAHDAC6
SCHEMBL16636475 0.77 CTSK (0.54) SLC6A2SLC6A4ALDH1A1KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SLC6A2 4308/4885SLC6A4 4386/4885ALDH1A1 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.